Yearly Archives: 2024

SAN FRANCISCO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Adaptive Research and Western Radiation Oncology (WRO) have announced that WRO has joined Adaptive Research’s growing network of community physician practices. This collaboration will expand access to innovative cancer treatment trials for patients across the San Francisco Bay Area.“We are pleased to welcome Western Radiation Oncology to our network,” stated Deepak Behera, MD, Chief Executive Officer of Adaptive Research. “By bringing clinical trials directly to community practices, we can provide patients with access to emerging therapies while advancing cancer research in real-world settings.”As part of Adaptive Research network, Western Radiation Oncology will receive comprehensive research administration, including dedicated project management, complete regulatory, compliance, and financial administration, research staffing, and technological solutions for patient recruitment and data management."We are enthusiastic about joining forces with Adaptive Research to provide our patients with access to promising, novel cancer treatment options," expressed Dr. Ankit Agarwal, MD, MBA, Medical Director at Western Radiation Oncology. "By actively participating in clinical trials, our patients not only have the opportunity to receive innovative investigational therapies but also contribute to the development of life-saving advancements in cancer care."This collaboration reflects Adaptive Research's mission to democratizing clinical trials by enabling community physicians to participate in clinical research. By providing comprehensive research support and mitigating logistical barriers for community practices like Western Radiation Oncology, Adaptive Research helps accelerate research and development for potentially life-altering cancer treatments while ensuring broader patient access to clinical trials.About Adaptive ResearchAdaptive Research, established in 2020, operates as a community-based clinical trials network that brings clinical research opportunities directly to local physician practices and their patients. The company serves as a virtual clinical trials office, providing the infrastructure, expertise, and administrative support needed for community physicians to participate in clinical research while focusing on patient care. Through its centralized…

SAN FRANCISCO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Adaptive Research, a clinical trial site organization dedicated to democratizing clinical trials, announced its participation in a groundbreaking decentralized study for Parkinsons’ Disease sponsored by PhotoPharmics Inc. California Movement Disorders Center, part of Adaptive Research’s network, will serve as a site for PhotoPharmics’ LIGHT-PD trial, testing the efficacy of Celeste® Specialized Phototherapy in treating Parkinson’s symptoms.Key Highlights:Decentralized trial design allows for remote monitoring through telehealth visitsDr. Kristin Andruska from Adaptive Research network to serve as investigatorStudy showcases the potential for community physicians to participate in advanced clinical trials "The decentralized approach of the LIGHT-PD trial is revolutionizing Parkinson's research," said study investigator Kristin Andruska, MD, PhD. "Using remote, home-based assessments, Adaptive Research can now include participants from a wide geography. This not only provides a more diverse patient population but also makes the trial accessible to those who might otherwise be unable to participate. It's an exciting step towards more inclusive clinical research."Deepak Behera, MD, CEO of Adaptive Research, added, "The at-home, telemedicine-based design of this trial aligns perfectly with Adaptive Research's vision for the future of clinical studies. It exemplifies our commitment to enhancing accessibility and convenience, enabling broader participation across diverse populations and geographies. Moreover, this study showcases how community physicians, when provided with the right support, can effectively contribute to cutting-edge, decentralized clinical trials."“LIGHT-PD will be the largest phototherapy trial of its kind and holds immense promise for those affected by Parkinson’s Disease and has received FDA Breakthrough Designation for its potential in improving PD symptoms. We welcome the California Movement Disorders Center and Adaptive Research to the ranks of movement disorder neurologists across the country who are enrolling and caring for trial participants,” said Dan Adams, CSO, PhotoPharmics, Inc.About the LIGHT-PD TrialThe LIGHT-PD trial (Double-blind, Randomized Controlled Trial to Demonstrate…

SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Adaptive Research, a clinical trial site organization whose mission is to democratize clinical trials by providing full-service support to trial investigators in community settings, announced two community practices that are part of the Adaptive Research network have begun patient enrollment and randomization in AriBio’s Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (POLARIS-AD). Noor Sachdev, MD and Perminder Bhatia, MD will serve as investigators with regulatory, finance, and clinical support for all study-related activities provided by Adaptive Research.“Studies such as this—which require participants to have signs and symptoms associated with the early stage of Alzheimer’s, such as some memory, planning, and organizational issues, and have a care partner who can accompany them to study visits—demonstrate the value of including community sites,” said Deepak Behera, MD, President and Chief Executive Officer of Adaptive Research. “Travel time to academic settings can contribute to inequalities in Alzheimer's disease clinical trial enrollment due to age, geography, and ethnicity. To recruit study populations that reflect the treatment population and make it easier for them to stay in the study, Sponsors need sites closer to patients that can produce quality data. In fact, community sites tend to know the patient population better resulting in a lower screen fail rate and better patient retainment compared to other settings.”“As we engage with interested investigators and sites across the world who are committed to making a difference in the treatment of patients with Alzheimer’s disease, we are pleased to have access to these community physicians who are on the front lines of patient care and often the first to see patients with early AD. These sites are paramount to running successful trials and providing access to diverse populations,” said James…

Partnership increases physician and patient participation in clinical trials